Johnson & Johnson (JNJ)
170.74
+0.00 (0.00%)
NYSE · Last Trade: Aug 6th, 4:41 AM EDT
Major Wall Street firms, including Morgan Stanley (NYSE: MS), Deutsche Bank AG (NYSE: DB), and Evercore ISI (NYSE: EVR), have issued cautionary advisories to their clients, signaling a potential stock market pullback of 10-15% in the third quarter of 2025. These warnings come on the heels of a robust rally
Via MarketMinute · August 5, 2025
While monthly jobs reports often grab headlines, savvy investors are increasingly looking beyond employment figures to a broader array of economic indicators for a more nuanced understanding of market health. Two such crucial metrics, Personal Consumption Expenditures (PCE) inflation and the Chicago Purchasing Managers' Index (PMI), are currently providing critical
Via MarketMinute · August 5, 2025
Concerns are mounting among financial analysts that the U.S. stock market may be entering an "overheated" phase, with equity valuations reaching levels that some deem unsustainable. This apprehension comes as major indices continue to flirt with record highs, prompting a critical debate about the market's current trajectory and its
Via MarketMinute · August 5, 2025
Johnson & Johnson (JNJ) is a top dividend stock with a 3.16% yield, consistent growth, and strong profitability, making it ideal for income investors seeking stability.
Via Chartmill · August 5, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
Via Benzinga · August 3, 2025
Can the stock still deliver the same kinds of returns it has over the past few decades?
Via The Motley Fool · August 2, 2025
Via Benzinga · August 1, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
Microsoft and Meta Platforms added over $400 billion in market capitalization after reporting robust earnings results on Wednesday.
Via Benzinga · July 31, 2025
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, with more data expected.
Via Benzinga · July 29, 2025
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.
Via Benzinga · July 29, 2025
These top Dow dividend stocks have long dividend growth streaks.
Via The Motley Fool · July 28, 2025
If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.
Via The Motley Fool · July 28, 2025
Plan now for a rotation away from riskier and volatile technology growth stocks and toward blue chips with more promise and predictability.
Via The Motley Fool · July 27, 2025
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
Via Benzinga · July 26, 2025
US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.
Via Benzinga · July 25, 2025
Artificial intelligence (AI) has become one of the most exciting and volatile sectors in the stock market. As companies like (NASDAQ:NVDA), (NASDAQ:PLTR), and (NASDAQ:TSLA) drive innovation in everything from chips to autonomous software, retail and institutional investors alike are piling into AI stocks at record levels. But
Via MarketMinute · July 25, 2025
In a market where volatility creates both fear and opportunity, income-focused investors are increasingly turning to a lesser-known but powerful strategy: selling cash-secured puts. This options strategy not only allows investors to generate steady income, but it also provides a disciplined way to potentially acquire stocks at prices below current
Via MarketMinute · July 25, 2025
With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.
Via MarketBeat · July 23, 2025
Via The Motley Fool · July 23, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Apple expands retail presence in Saudi Arabia by launching online store and app, offering personalized support and localized experience.
Via Benzinga · July 22, 2025